Global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Attention Deficit Hyperactivity Treatment Disorder
Attention deficit hyperactivity disorder is one of the most common brain disorder characterized by impairing and pervasive symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (<12 years age) as compared to adolescents. It is also known as hyperkinetic disorder/attention deficit disorder or neuropsychiatric disorder. The exact cause of the Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be resulted due to genetic factors and environmental influences. It results in improper functioning of the nervous system that led to attention deficit and hyperactivity/impulsiveness condition. The major symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The treatment includes different modalities such as medication, psychotherapy, and education/training.
The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is growing at a significant CAGR due to changing in lifestyle and systems impacting the quality of the births. Increase in the use of preservatives and additives in children’s diet, an increase in the prevalence of attention deficit hyperactivity disorder among children about 4–17 year age group expected to fuel the growth of attention deficit hyperactivity disorder treatment market over the forecast period. Moreover, increase in the adoption rate of diagnostic guidelines, increasing awareness among patients and physicians about attention deficit hyperactivity disorder treatment are expected to bolster the revenue growth of attention deficit hyperactivity disorder treatment therapeutics market over the forecast period. However, the presence of comorbid conditions in children leads to underdiagnoses of attention deficit hyperactivity disorder treatment, lack of availability of non-stimulant drugs, stringent regulatory guidelines, and a high cost of the medication are expected to hamper the growth of attention deficit hyperactivity disorder treatment market over the forecast period.
The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is segmented on the basis of medication type, age group, and distribution channel
Based on medication type, the Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market has been segmented into following:
Globally, the attention deficit hyperactivity disorder treatment market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in global attention deficit hyperactivity disorder treatment market followed by Europe and Asia-Pacific. North America holds the largest share attributed to rising prevalence of attention deficit hyperactivity disorder, low threshold of diagnosis is expected to boost the of attention deficit hyperactivity disorder treatment therapeutics market in North America region over the forecast period. Moreover, increase in healthcare expenditure, ongoing clinical trials, early approval of drugs in the U.S., favourable insurance policies for brain monitoring technologies, and technological advancement for the treatment might fuel the attention deficit hyperactivity disorder treatment market. Europe accounts for the significant share attributed to increase in the population, rising prevalence of attention deficit hyperactivity disorder patients, and increased in research and development for the innovation of new products. Asia-Pacific holds a dominant share in attention deficit hyperactivity disorder treatment market owing to developing healthcare infrastructure, government initiatives, a rise in population, and an increase in the number of mental disorders. Japan is the key region in attention deficit hyperactivity disorder treatment market owing to increase in the prevalence of attention deficit hyperactivity disorder among children which is approximately 7.7 %.
Some of the key players in the global attention deficit hyperactivity disorder treatment market are Neos Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Supernus Pharmaceuticals, Inc. (U.S.),Shire plc (Ireland), MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.) and Actavis (U.S.) to name a few.
In June 2017, Shire Plc received U.S. FDA approval for a long-acting attention-deficit drug Adderall XR aimed at adolescents and adults
In December 2015, Pfizer received U.S. Food and Drug Administration approval of Quillichew ER for attention deficit hyperactivity disorder treatment
Report Outline:
Attention deficit hyperactivity disorder is one of the most common brain disorder characterized by impairing and pervasive symptoms of hyperactivity, inattention, and impulsivity. It is commonly observed in children (<12 years age) as compared to adolescents. It is also known as hyperkinetic disorder/attention deficit disorder or neuropsychiatric disorder. The exact cause of the Attention Deficit Hyperactivity Disorder (ADHD) is not clear but, expected to be resulted due to genetic factors and environmental influences. It results in improper functioning of the nervous system that led to attention deficit and hyperactivity/impulsiveness condition. The major symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The treatment includes different modalities such as medication, psychotherapy, and education/training.
The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is growing at a significant CAGR due to changing in lifestyle and systems impacting the quality of the births. Increase in the use of preservatives and additives in children’s diet, an increase in the prevalence of attention deficit hyperactivity disorder among children about 4–17 year age group expected to fuel the growth of attention deficit hyperactivity disorder treatment market over the forecast period. Moreover, increase in the adoption rate of diagnostic guidelines, increasing awareness among patients and physicians about attention deficit hyperactivity disorder treatment are expected to bolster the revenue growth of attention deficit hyperactivity disorder treatment therapeutics market over the forecast period. However, the presence of comorbid conditions in children leads to underdiagnoses of attention deficit hyperactivity disorder treatment, lack of availability of non-stimulant drugs, stringent regulatory guidelines, and a high cost of the medication are expected to hamper the growth of attention deficit hyperactivity disorder treatment market over the forecast period.
The global Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market is segmented on the basis of medication type, age group, and distribution channel
Based on medication type, the Attention Deficit Hyperactivity Treatment Disorder (ADHD) Market has been segmented into following:
- Stimulants
- Amphetamines
- Methylphenidate
- Dextroamphetamine
- Dexmethylphenidate
- Non-Stimulants
- Atomoxetine
- Bupropion
- Guanfacine
- Paediatric
- Adolescent
- Adults
- Hospital pharmacies
- Specialty clinics
- Retail pharmacies
- Online pharmacies
Globally, the attention deficit hyperactivity disorder treatment market has been segmented into the following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America holds the largest share in global attention deficit hyperactivity disorder treatment market followed by Europe and Asia-Pacific. North America holds the largest share attributed to rising prevalence of attention deficit hyperactivity disorder, low threshold of diagnosis is expected to boost the of attention deficit hyperactivity disorder treatment therapeutics market in North America region over the forecast period. Moreover, increase in healthcare expenditure, ongoing clinical trials, early approval of drugs in the U.S., favourable insurance policies for brain monitoring technologies, and technological advancement for the treatment might fuel the attention deficit hyperactivity disorder treatment market. Europe accounts for the significant share attributed to increase in the population, rising prevalence of attention deficit hyperactivity disorder patients, and increased in research and development for the innovation of new products. Asia-Pacific holds a dominant share in attention deficit hyperactivity disorder treatment market owing to developing healthcare infrastructure, government initiatives, a rise in population, and an increase in the number of mental disorders. Japan is the key region in attention deficit hyperactivity disorder treatment market owing to increase in the prevalence of attention deficit hyperactivity disorder among children which is approximately 7.7 %.
Some of the key players in the global attention deficit hyperactivity disorder treatment market are Neos Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Supernus Pharmaceuticals, Inc. (U.S.),Shire plc (Ireland), MonoSol Rx(U.S.), KemPharm, Inc. (U.S.), Neurosigma, Inc. (U.S.) and Actavis (U.S.) to name a few.
In June 2017, Shire Plc received U.S. FDA approval for a long-acting attention-deficit drug Adderall XR aimed at adolescents and adults
In December 2015, Pfizer received U.S. Food and Drug Administration approval of Quillichew ER for attention deficit hyperactivity disorder treatment
Report Outline:
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET INTRODUCTION
2.1. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Taxonomy
2.2. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market -Definitions
2.2.1. Drug Class
2.2.2. Age Group
2.2.3. Distribution Channel
3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Factors Impact Analysis
3.6. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Product Innovations
4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Stimulants
5.1.1. Amphetamines
5.1.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Methylphenidate
5.1.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Dextroamphetamine
5.1.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Dexmethylphenidate
5.1.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
5.2. Non-Stimulants
5.2.1. Atomoxetine
5.2.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.1.3. Market Opportunity Analysis
5.2.2. Bupropion
5.2.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.2.3. Market Opportunity Analysis
5.2.3. Guanfacine
5.2.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3.3. Market Opportunity Analysis
6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET FORECAST, BY AGE GROUP, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Paediatric
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Adolescent
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Adults
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Specialty Clinics
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type, Age Group, Distribution Channel and Region, 2017 - 2023
9. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Stimulants
9.1.1.1. Amphetamines
9.1.1.2. Methylphenidate
9.1.1.3. Dextroamphetamine
9.1.1.4. Dexmethylphenidate
9.1.2. Non-Stimulants
9.1.2.1. Atomoxetine
9.1.2.2. Bupropion
9.1.2.3. Guanfacine
9.1.2.4. Others
9.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Paediatric
9.2.2. Adolescent
9.2.3. Adults
9.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Specialty Clinics
9.3.3. Retail Pharmacies
9.3.4. Online Pharmacies
9.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
9.6. North America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
10. EUROPE ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Stimulants
10.1.1.1. Amphetamines
10.1.1.2. Methylphenidate
10.1.1.3. Dextroamphetamine
10.1.1.4. Dexmethylphenidate
10.1.2. Non-Stimulants
10.1.2.1. Atomoxetine
10.1.2.2. Bupropion
10.1.2.3. Guanfacine
10.1.2.4. Others
10.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Paediatric
10.2.2. Adolescent
10.2.3. Adults
10.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Specialty Clinics
10.3.3. Retail Pharmacies
10.3.4. Online Pharmacies
10.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
10.6. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
11. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Stimulants
11.1.1.1. Amphetamines
11.1.1.2. Methylphenidate
11.1.1.3. Dextroamphetamine
11.1.1.4. Dexmethylphenidate
11.1.2. Non-Stimulants
11.1.2.1. Atomoxetine
11.1.2.2. Bupropion
11.1.2.3. Guanfacine
11.1.2.4. Others
11.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Paediatric
11.2.2. Adolescent
11.2.3. Adults
11.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Specialty Clinics
11.3.3. Retail Pharmacies
11.3.4. Online Pharmacies
11.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
11.6. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
12. LATIN AMERICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Stimulants
12.1.1.1. Amphetamines
12.1.1.2. Methylphenidate
12.1.1.3. Dextroamphetamine
12.1.1.4. Dexmethylphenidate
12.1.2. Non-Stimulants
12.1.2.1. Atomoxetine
12.1.2.2. Bupropion
12.1.2.3. Guanfacine
12.1.2.4. Others
12.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Paediatric
12.2.2. Adolescent
12.2.3. Adults
12.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Specialty Clinics
12.3.3. Retail Pharmacies
12.3.4. Online Pharmacies
12.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
12.6. Latin America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
13. MIDDLE EAST AND AFRICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Stimulants
13.1.1.1. Amphetamines
13.1.1.2. Methylphenidate
13.1.1.3. Dextroamphetamine
13.1.1.4. Dexmethylphenidate
13.1.2. Non-Stimulants
13.1.2.1. Atomoxetine
13.1.2.2. Bupropion
13.1.2.3. Guanfacine
13.1.2.4. Others
13.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Paediatric
13.2.2. Adolescent
13.2.3. Adults
13.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Specialty Clinics
13.3.3. Retail Pharmacies
13.3.4. Online Pharmacies
13.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Argentina
13.4.4. Venezuela
13.4.5. Rest of Latin America
13.5. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.5.1. Gulf Cooperation Council (GCC) Countries
13.5.2. Israel
13.5.3. South Africa
13.5.4. Rest of MEA
13.6. MEA Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel and Country, 2017 - 2023
13.7. MEA Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Allergan, Inc. (U.S.)
14.2.2. Medtronic. (Covidien PLC) (U.S.)
14.2.3. EnteroMedics, Inc (U.S.)
14.2.4. Cousin Biotech (France)
14.2.5. Surgical IOC (Peters Surgical SAS) (France)
14.2.6. PARE Surgical Inc. (U.S.)
14.2.7. GI Dynamics (U.S.)
15. RESEARCH METHODOLOGY
Key Assumptions and Acronyms
2. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET INTRODUCTION
2.1. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Taxonomy
2.2. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market -Definitions
2.2.1. Drug Class
2.2.2. Age Group
2.2.3. Distribution Channel
3. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Factors Impact Analysis
3.6. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Product Innovations
4. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET, BY DRUG TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. Stimulants
5.1.1. Amphetamines
5.1.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.1.3. Market Opportunity Analysis
5.1.2. Methylphenidate
5.1.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.2.3. Market Opportunity Analysis
5.1.3. Dextroamphetamine
5.1.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3.3. Market Opportunity Analysis
5.1.4. Dexmethylphenidate
5.1.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.4.3. Market Opportunity Analysis
5.2. Non-Stimulants
5.2.1. Atomoxetine
5.2.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.1.3. Market Opportunity Analysis
5.2.2. Bupropion
5.2.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.2.3. Market Opportunity Analysis
5.2.3. Guanfacine
5.2.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3.3. Market Opportunity Analysis
6. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET FORECAST, BY AGE GROUP, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Paediatric
6.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Market Opportunity Analysis
6.2. Adolescent
6.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Market Opportunity Analysis
6.3. Adults
6.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.3.3. Market Opportunity Analysis
7. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Retail Pharmacies
7.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
7.4. Specialty Clinics
7.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.4.3. Market Opportunity Analysis
8. GLOBAL ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD) MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. North America
8.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type, Age Group, Distribution Channel and Region, 2017 - 2023
9. NORTH AMERICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Stimulants
9.1.1.1. Amphetamines
9.1.1.2. Methylphenidate
9.1.1.3. Dextroamphetamine
9.1.1.4. Dexmethylphenidate
9.1.2. Non-Stimulants
9.1.2.1. Atomoxetine
9.1.2.2. Bupropion
9.1.2.3. Guanfacine
9.1.2.4. Others
9.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.2.1. Paediatric
9.2.2. Adolescent
9.2.3. Adults
9.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Specialty Clinics
9.3.3. Retail Pharmacies
9.3.4. Online Pharmacies
9.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
9.6. North America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
10. EUROPE ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Stimulants
10.1.1.1. Amphetamines
10.1.1.2. Methylphenidate
10.1.1.3. Dextroamphetamine
10.1.1.4. Dexmethylphenidate
10.1.2. Non-Stimulants
10.1.2.1. Atomoxetine
10.1.2.2. Bupropion
10.1.2.3. Guanfacine
10.1.2.4. Others
10.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.2.1. Paediatric
10.2.2. Adolescent
10.2.3. Adults
10.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Specialty Clinics
10.3.3. Retail Pharmacies
10.3.4. Online Pharmacies
10.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
10.6. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
11. ASIA-PACIFIC ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1. Drug Class Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Stimulants
11.1.1.1. Amphetamines
11.1.1.2. Methylphenidate
11.1.1.3. Dextroamphetamine
11.1.1.4. Dexmethylphenidate
11.1.2. Non-Stimulants
11.1.2.1. Atomoxetine
11.1.2.2. Bupropion
11.1.2.3. Guanfacine
11.1.2.4. Others
11.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.2.1. Paediatric
11.2.2. Adolescent
11.2.3. Adults
11.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Specialty Clinics
11.3.3. Retail Pharmacies
11.3.4. Online Pharmacies
11.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
11.6. Europe Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
12. LATIN AMERICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Stimulants
12.1.1.1. Amphetamines
12.1.1.2. Methylphenidate
12.1.1.3. Dextroamphetamine
12.1.1.4. Dexmethylphenidate
12.1.2. Non-Stimulants
12.1.2.1. Atomoxetine
12.1.2.2. Bupropion
12.1.2.3. Guanfacine
12.1.2.4. Others
12.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.2.1. Paediatric
12.2.2. Adolescent
12.2.3. Adults
12.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Specialty Clinics
12.3.3. Retail Pharmacies
12.3.4. Online Pharmacies
12.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel, and Country, 2017 - 2023
12.6. Latin America Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
13. MIDDLE EAST AND AFRICA ATTENTION DEFICIT HYPERACTIVITY TREATMENT DISORDER (ADHD)MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Stimulants
13.1.1.1. Amphetamines
13.1.1.2. Methylphenidate
13.1.1.3. Dextroamphetamine
13.1.1.4. Dexmethylphenidate
13.1.2. Non-Stimulants
13.1.2.1. Atomoxetine
13.1.2.2. Bupropion
13.1.2.3. Guanfacine
13.1.2.4. Others
13.2. Age Group Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.2.1. Paediatric
13.2.2. Adolescent
13.2.3. Adults
13.3. Distribution Channel Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Specialty Clinics
13.3.3. Retail Pharmacies
13.3.4. Online Pharmacies
13.4. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Argentina
13.4.4. Venezuela
13.4.5. Rest of Latin America
13.5. Country Analysis (2012 - 2016) and Forecast (2017 - 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.5.1. Gulf Cooperation Council (GCC) Countries
13.5.2. Israel
13.5.3. South Africa
13.5.4. Rest of MEA
13.6. MEA Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market - Opportunity Analysis Index, By Drug Type Analysis, Age Group, Distribution Channel and Country, 2017 - 2023
13.7. MEA Attention Deficit Hyperactivity Treatment Disorder (ADHD)Market Dynamics - Trends
14. COMPETITION LANDSCAPE
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Allergan, Inc. (U.S.)
14.2.2. Medtronic. (Covidien PLC) (U.S.)
14.2.3. EnteroMedics, Inc (U.S.)
14.2.4. Cousin Biotech (France)
14.2.5. Surgical IOC (Peters Surgical SAS) (France)
14.2.6. PARE Surgical Inc. (U.S.)
14.2.7. GI Dynamics (U.S.)
15. RESEARCH METHODOLOGY
Key Assumptions and Acronyms
